Novartis AG Common Stock (NVS)

Total Assets

$122.03B

Quarterly · Period ending: · USD

NVS logo

NVS Total Assets

Latest reported$122.03B
NVS Quarterly Total Assets ($38.74B → $122.03B)
High-resolution chart · PNG

NVS total assets history

Quarterly · USD. Dates are reporting period ends; fiscal years can differ from calendar years.

Novartis AG Common Stock Total Assets — Quarterly (USD)
Period endingTotal Assets (USD)
122,033,489,000
118,532,000,000
115,569,198,000
107,289,000,000
104,395,000,000
99,941,000,000
102,246,000,000
103,524,000,000
97,505,000,000
94,334,000,000
103,823,795,570
112,697,000,000
110,979,000,000
112,241,000,000
121,765,294,671
118,464,000,000
122,910,000,000
125,218,000,000
135,884,000,000
121,209,000,000
124,015,000,000
121,752,000,000
132,189,000,000
129,678,000,000
123,763,000,000
123,097,000,000
118,412,488,219
115,971,000,000
116,294,000,000
137,946,000,000
145,563,000,000
142,994,000,000
142,058,000,000
135,524,000,000
133,079,000,000
134,972,000,000
133,749,000,000
131,986,000,000
130,124,000,000
134,007,000,000
131,436,000,000
132,448,000,000
131,556,000,000
132,927,000,000
135,413,000,000
134,935,000,000
125,387,000,000
125,377,000,000
125,768,000,000
125,332,000,000
126,254,000,000
124,594,000,000
121,072,000,000
121,011,000,000
124,216,000,000
121,219,000,000
118,492,000,000
119,411,000,000
117,496,000,000
121,377,000,000
125,915,000,000
127,218,000,000
123,318,000,000
124,628,000,000
96,924,000,000
95,795,000,000
95,505,000,000
90,686,000,000
84,274,000,000
77,970,000,000
78,299,000,000
82,020,000,000
83,399,000,000
76,318,000,000
75,452,000,000
76,936,000,000
70,621,000,000
68,324,000,000
68,008,000,000
66,862,000,000
65,929,000,000
58,848,000,000
57,732,000,000
54,670,000,000
53,043,000,000
49,646,000,000
54,469,000,000
49,538,000,000
48,633,000,000
48,267,000,000
49,317,000,000
46,329,000,000
45,637,000,000
46,662,000,000
45,144,000,000
41,116,000,000
43,077,000,000
40,305,000,000
34,471,000,000
35,484,000,000
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.